Visceral Adiposity and Ectopic Fat

Definition

Visceral adiposity refers to excess intra-abdominal fat (visceral adipose tissue, VAT), which is distinct from subcutaneous adipose tissue and constitutes an independent cardiovascular risk marker. Ectopic fat refers to lipid deposits in sites not physiologically designed for fat storage — including the liver, pancreas, heart, and skeletal muscle. Pericardial and epicardial adipose tissues are the most clinically relevant cardiac ectopic fat depots. (sources/obesity-cv-aha-2021, rating: very high)

Key Concepts

Visceral Adipose Tissue (VAT) as a CVD Risk Marker

• At any BMI level, there is 2- to 3-fold individual variation in VAT; some individuals with high BMI have low VAT ("metabolically healthy obesity") while others with normal BMI have high VAT. (sources/obesity-cv-aha-2021, rating: very high)
• Excess VAT (vs metabolically healthy obesity) is associated with the highest CVD risk, regardless of BMI. Metabolically healthy obesity may be a transient phenotype — the majority of individuals progress to metabolically unhealthy obesity over time, with variation by race/ethnicity and sex. (sources/obesity-cv-aha-2021, rating: very high)
• All fat depots (VAT, subcutaneous, pericardial, epicardial, hepatic) are correlated with one another, but VAT has the strongest independent association with cardiometabolic risk factors. (sources/obesity-cv-aha-2021, rating: very high)
• VAT promotes systemic and vascular inflammation → LDL oxidation → atherogenesis; activates the RAAS and sympathetic nervous system → elevated blood pressure; induces insulin resistance → dyslipidemia and metabolic syndrome. (sources/obesity-cv-aha-2021, rating: very high)

Clinical Measures of Visceral Adiposity

• Waist circumference (WC): Practical clinical proxy for abdominal/VAT burden. High WC at any BMI (including normal weight) is independently associated with CVD risk and mortality. Multiple organizations recommend WC alongside BMI. (sources/obesity-cv-aha-2021, rating: very high)
• Waist-to-height ratio: May be a better CVD predictor than WC alone by accounting for body size. (sources/obesity-cv-aha-2021, rating: very high)
• Waist-to-hip ratio (WHR): Independently predicts cardiovascular mortality; those with central obesity by WHR criteria have higher cardiovascular mortality at the same BMI. (sources/obesity-cv-aha-2021, rating: very high)
• CT/MRI: Gold standard for quantifying VAT, subcutaneous fat, and ectopic fat volumes; enables precise risk stratification but not practical for routine clinical use. (sources/obesity-cv-aha-2021, rating: very high)

Pericardial Fat

• Total fat content within the pericardial sac (below the superior extent of the main coronary arteries); quantified by CT.
• Associated with higher BMI, traditional CVD risk factors, and atherogenic lipoprotein particles.
• In MESA: pericardial fat associated with all-cause CVD, atherosclerotic CVD, and HF; adding pericardial fat to clinical parameters + CAC score improved risk discrimination.
• Rancho Bernardo Study: all-cause mortality increased 34% per 1-SD increment in pericardial fat (adjusted); however, pericardial fat did not independently predict incident CVD beyond traditional risk factors in this study.
  (sources/obesity-cv-aha-2021, rating: very high)

Epicardial Adipose Tissue (EAT)

• Visceral fat between the outer wall of the myocardium and the visceral pericardium; originates from splanchnopleuric mesoderm via epicardial progenitor epithelial-to-mesenchymal transition; no fascial barrier from the myocardium — direct crosstalk with cardiomyocytes. Average EAT = ~20% of total heart weight; EAT volume increases with BMI after age 40. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• Associated with: overall cardiovascular health score, arterial stiffness in CVD + T2DM, WC, blood pressure, insulin resistance markers, dyslipidemia, sleep apnea severity (independently of BMI). (sources/obesity-cv-aha-2021, rating: very high)
• EAT and AF: EAT is a proarrhythmic substrate through three mechanisms: (1) structural infiltration of the myocardium creating "zigzag" conduction barriers, fractionated electrograms, and re-entry substrate; (2) potential Cx43-mediated electrotonic coupling to cardiomyocytes altering resting membrane potential; (3) paracrine secretome (adipokines + EVs) that prolongs APD, downregulates connexins, and drives fibrosis. The EAT–AF association is stronger than overall or abdominal obesity–AF association. See concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high; sources/obesity-cv-aha-2021, rating: very high)
• Key proarrhythmic adipokines from EAT: TNF-α and IL-1β reduce Ito → APD prolongation; IL-6 modulates ICaL and SERCA2a; IL-1β/IL-6/TNF-α downregulate Cx43/Cx40 → gap junction remodeling and conduction slowing; activin A, TGF-β1, visfatin, leptin, MCP-1 → fibroblast proliferation, collagen synthesis, myofibroblast activation → fibrosis. EVs from AF patients' epicardial fat contain profibrotic miRNAs and shorten APD in hiPSC-CMs. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• ECG correlates of EAT volume: Prolonged P-wave duration and dispersion (atrial conduction delay), prolonged PR interval (10–16 ms in highest vs lowest EAT tertile), prolonged QRS and fragmented QRS, and increased Tpeak–Tend interval + QT dispersion (repolarisation heterogeneity). (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• EAT and SCD: EAT associated with premature ventricular contractions, VT/VF, all-cause long-term mortality, and SCD mortality; EAT infiltrations into atrial and ventricular myocardium → fibrosis → reentrant arrhythmic circuits. (sources/obesity-cv-aha-2021, rating: very high)
• EAT and HFpEF: Greater EAT thickness and volume in obesity-HFpEF vs non-obese HFpEF; contributes to pericardial restraint and ventricular interdependence as part of the distinct obesity-HFpEF phenotype. (sources/obesity-cv-aha-2021, rating: very high)

Hepatic Fat (NAFLD)

• Excess liver fat (nonalcoholic fatty liver disease) is frequently coexistent with visceral obesity; associated with the same CVD risk factor alterations as VAT.
• Mendelian randomisation studies of genetic variants predisposing to liver fat accumulation have not confirmed an independent causal association with CVD — the relationship may be mediated by shared VAT mechanisms rather than liver fat per se.
  (sources/obesity-cv-aha-2021, rating: very high)

Noncalcified Coronary Plaque and VAT

• Abdominal visceral adiposity independently predicts the presence and extent of noncalcified coronary plaque with multiple vulnerability features (positive remodeling, spotty calcification, low-attenuation plaque) — independent of traditional cardiovascular risk factors.
• In CT coronary angiography registries: highest quartile of visceral adiposity carries the greatest risk of noncalcified plaque accumulation.
  (sources/obesity-cv-aha-2021, rating: very high)

Impact of Lifestyle Interventions on Ectopic Fat

• Exercise: Aerobic exercise (3–5 sessions/week for 12–52 weeks) reduces VAT by ~6.1% even in the absence of weight loss (meta-analysis); 150 min/week may be sufficient. High-intensity vs moderate-intensity exercise data are inconsistent. (sources/obesity-cv-aha-2021, rating: very high)
• Diet: Caloric restriction reduces VAT and hepatic fat; exercise appears superior to diet alone for VAT reduction in most studies. (sources/obesity-cv-aha-2021, rating: very high)
• Combined lifestyle interventions: Diabetes Prevention Program and Look AHEAD report greater VAT reductions vs control groups. (sources/obesity-cv-aha-2021, rating: very high)
• Epicardial fat: Exercise and caloric restriction reduce epicardial fat; meta-analysis showed non-significant reduction with exercise alone. CPAP reduces epicardial fat in sleep apnoea, but short-term CPAP (8–12 weeks) does not affect VAT. (sources/obesity-cv-aha-2021, rating: very high)

Contradictions / Open Questions

• Pericardial vs epicardial fat terminology: Often used interchangeably in the literature but have distinct anatomic locations and functions. Pericardial fat = total fat within pericardial sac; EAT = fat between myocardium and visceral pericardium. (sources/obesity-cv-aha-2021, rating: very high)
• EAT causality in arrhythmia: Whether thicker epicardial fat is a predictor or a consequence of sleep-disordered breathing and/or AF itself remains uncertain. AF induces fibro-fatty infiltration fibrosis in sheep — EAT may be both cause and consequence of AF. (sources/obesity-cv-aha-2021, rating: very high; sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• EAT and QTc discrepancy: In vitro EAT secretome clearly prolongs APD (reduced IKr/Ito, increased INaLate/ICaL) — yet 3 of 4 observational ECG studies show no QTc association with EAT volume, with one study even reporting an inverse relationship. The translation from cellular APD prolongation to surface QTc in humans is unresolved. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• EAT adipocyte-cardiomyocyte electrotonic coupling: Both express Cx43 and coupling is mechanistically plausible, but entirely unproven in intact human tissue — currently an inference from fibroblast-myocyte and macrophage-myocyte coupling experiments. (sources/epi-adipose-arrhythmia-jacc-2021, rating: high)
• Liver fat and CVD: Mendelian randomisation does not confirm independent causal CVD risk from liver fat; observational associations may reflect shared metabolic pathway with VAT rather than direct liver fat effect. (sources/obesity-cv-aha-2021, rating: very high)
• Exercise dose for VAT reduction: Not all studies show significant VAT reduction with exercise vs control; the dose-response relationship and whether resistance training alone is effective remain unresolved. (sources/obesity-cv-aha-2021, rating: very high)

Connections

• Related to entities/Obesity — visceral adiposity as the key mechanistic link to CVD risk
• Related to entities/Atrial-Fibrillation — EAT as the primary adiposity-AF substrate
• Related to concepts/Epicardial-Adipose-Tissue-Arrhythmogenesis — detailed mechanistic pathways by which EAT causes arrhythmias
• Related to concepts/HFpEF — EAT contributes to obesity-HFpEF phenotype
• Related to concepts/Sudden-Cardiac-Death — EAT → fibrosis → VT/VF substrate
• Related to entities/Heart-Failure — VAT-driven hemodynamic changes and myocardial effects
• Related to concepts/OSA-Arrhythmogenic-Substrate — EAT and sleep apnoea interaction
• Related to entities/Obstructive-Sleep-Apnea — EAT and sleep apnoea severity independent of BMI

Sources

• sources/epi-adipose-arrhythmia-jacc-2021
• sources/obesity-cv-aha-2021